Maya Hites

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/938621/publications.pdf

Version: 2024-02-01

		759233	642732
25	619	12	23
papers	citations	h-index	g-index
27	27	27	010
27	27	27	810
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Perioperative antimicrobial prophylaxis in patients undergoing pancreatoduodenectomy: retrospective analysis of bacteriological profile and susceptibility. Acta Chirurgica Belgica, 2023, 123, 337-344.	0.4	1
2	Worsening of COVID-19 after chemotherapy in patients considered to have recovered from a SARS-CoV-2 infection. Leukemia and Lymphoma, 2022, 63, 253-255.	1.3	1
3	Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group. Clinical Microbiology and Infection, 2022, 28, 1-5.	6.0	15
4	Accelerating clinical trial implementation in the context of the COVID-19 pandemic: author's response. Clinical Microbiology and Infection, 2022, , .	6.0	0
5	Ensuring target concentrations of antibiotics in critically ill patients through dose adjustment. Expert Opinion on Drug Metabolism and Toxicology, 2022, 18, 177-187.	3.3	5
6	Drug Regimens of Novel Antibiotics in Critically Ill Patients with Varying Renal Functions: A Rapid Review. Antibiotics, 2022, $11,546$.	3.7	9
7	A Retrospective, Monocentric Study Comparing Co and Secondary Infections in Critically Ill COVID-19 and Influenza Patients. Antibiotics, 2022, 11, 704.	3.7	2
8	Pharmacological Studies in Hospitalized COVID-19 Patients in Belgium: We Could Do Better. Viruses, 2022, 14, 1427.	3.3	1
9	Invasive group B Streptococcus among non-pregnant adults in Brussels-Capital Region, 2005–2019. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 515-523.	2.9	23
10	Minireview on Novel Anti-infectious Treatment Options and Optimized Drug Regimens for Sepsis. Frontiers in Medicine, 2021, 8, 640740.	2.6	8
11	Case Report: About a Case of Hyperammonemia Syndrome Following Lung Transplantation: Could Metagenomic Next-Generation Sequencing Improve the Clinical Management?. Frontiers in Medicine, 2021, 8, 684040.	2.6	8
12	Plasma zinc status and hyperinflammatory syndrome in hospitalized COVID-19 patients: An observational study. International Immunopharmacology, 2021, 100, 108163.	3.8	9
13	Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. Lancet Respiratory Medicine,the, 2021, 9, 1427-1438.	10.7	86
14	Perioperative antimicrobial prophylaxis in patients undergoing pancreatoduodenectomy: retrospective analysis of bacteriological profile and susceptibility. Acta Chirurgica Belgica, 2021, , 1-12.	0.4	0
15	Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents. Clinical Pharmacokinetics. 2020. 59. 1195-1216.	3. 5	28
16	What is the optimal loading dose of broad-spectrum β-lactam antibiotics in septic patients? Results from pharmacokinetic simulation modelling. International Journal of Antimicrobial Agents, 2020, 56, 106113.	2.5	17
17	Treatment of ventilator-associated pneumonia with high-dose colistin under continuous veno-venous hemofiltration. Journal of Translational Internal Medicine, 2019, 7, 100-105.	2.5	7
18	Optimizing \hat{l}^2 -lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?. Expert Review of Anti-Infective Therapy, 2017, 15, 677-688.	4.4	77

Maya Hites

#	Article	IF	CITATION
19	Serum βâ€lactam concentrations in critically ill patients with cirrhosis: a matched case–control study. Liver International, 2016, 36, 1002-1010.	3.9	12
20	New Regimen for Continuous Infusion of Vancomycin in Critically III Patients. Antimicrobial Agents and Chemotherapy, 2016, 60, 4750-4756.	3.2	45
21	Evaluation of total body weight and body mass index cut-offs for increased cefazolin dose for surgical prophylaxis. International Journal of Antimicrobial Agents, 2016, 48, 633-640.	2.5	16
22	Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: A structured review. International Journal of Antimicrobial Agents, 2016, 47, 259-268.	2.5	94
23	A high-dose aminoglycoside regimen combined with renal replacement therapy for the treatment of MDR pathogens: a proof-of-concept study. Journal of Antimicrobial Chemotherapy, 2016, 71, 1386-1394.	3.0	27
24	The challenges of multiple organ dysfunction syndrome and extra-corporeal circuits for drug delivery in critically ill patients. Advanced Drug Delivery Reviews, 2014, 77, 12-21.	13.7	33
25	Case-Control Study of Drug Monitoring of \hat{l}^2 -Lactams in Obese Critically Ill Patients. Antimicrobial Agents and Chemotherapy, 2013, 57, 708-715.	3.2	92